Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 4
Submit an article Journal homepage
260
Views
26
CrossRef citations to date
0
Altmetric
Research Report

Sativex® in multiple sclerosis spasticity: a cost–effectiveness model

John Slof Universitat Autònoma de Barcelona, Campus de la UAB, 08193 Bellaterra, Spain; Universitat Autònoma de Barcelona, Campus de la UAB, 08193 Bellaterra, Spain
&
Adrien Gras GfK Bridgehead, Marble Arch Tower, 19th Floor, 55 Bryanston Street, W1H 7AA, UK. [email protected]; GfK Bridgehead, Marble Arch Tower, 19th Floor, 55 Bryanston Street, W1H 7AA, UK. [email protected]
Pages 439-441 | Published online: 09 Jan 2014

References

  • Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol. 13, 700–722 (2006).
  • Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? Q. J. Med. 97, 671–676 (2004).
  • Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the “5E” study. Expert Rev. Pharmacoecon. Outcomes Res. 11(2), 205–213 (2011).
  • Buhse M. Assessment of caregiver burden in families of persons with multiple sclerosis. J. Neurosci. Nurs. 40, 25–31 (2008).
  • Sobocki P, Pugliatti M, Lauer K, Kobelt G. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult. Scler. 13(8), 1054–1064 (2007).
  • Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol. 12(Suppl. 1), 1–27 (2005).
  • Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 10, 589–595 (2004).
  • Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv. Ther. 26(12), 1043–1057 (2009).
  • Bavikatte G, Gaber T. Approach to spasticity in general practice. Br. J. Med. Pract. 2(3), 29–34 (2009).
  • Stevenson VL. Rehabilitation in practice: spasticity management. Clin. Rehabil. 24, 293–304 (2010).
  • Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc.) 42, 495–501 (2006).
  • Collin C, Davies P, Mutiboko IK et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 14, 290–296 (2007).
  • Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 12, S111–S112 (2010).
  • Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the effects of Sativex® on spasticity associated with multiple sclerosis. Mult. Scler. 16(6), 707–714 (2006).
  • Novotna A, Mares J, Ratcliffe S et al. A randomised, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18(9), 1122–1131 (2011).
  • Farrar J, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther. 30(5), 974–985 (2008).
  • Bodrogi J, Kaló Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br. J. Pharmacol. 159(7), 1367–1373 (2010).
  • Malone DC. The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines. J. Manag. Care Pharm. 11(Suppl. 4), S7–S10 (2005).
  • Bravo Vergel Y, Sculpher M. Quality-adjusted life years. Pract. Neurol. 8(3), 175–182 (2008).
  • Sonnenberg F, Beck J. Markov models in medical decision making. Med. Decision Making 13(4), 322–329 (1993).
  • Sativex® oromucosal spray: summary of product characteristics. Almirall, Spain (2010).
  • Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis 12, 639–645 (2006).
  • Hasson F, Keeney S, McKenna HP. Research guidelines for the Delphi survey technique. J. Adv. Nurs. 32(4), 1008–1015 (2000).
  • Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. Int. J. Forecasting 15, 353–375 (1999).
  • McBride AJ, Pates R, Ramadan R, McGowan C. Delphi survey of experts' opinions on strategies used by community pharmacists to reduce over-the-counter drug misuse. Addiction 98(4), 487–497 (2003).
  • UK MHRA Sativex registry study. Data on file. Almirall, Spain.
  • Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psych. 77, 918–926 (2006).
  • Postma TJ, Oenema D, Terpstra S et al. Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system. Pharmacoeconomics 15(4), 395–404 (1999).
  • MOVE 1 epidemiological study. Data on file. Almirall, Spain.
  • McCrone P, Heslin M, Knapp M, Bull P, Thompson A. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 26(10), 847–860 (2008).
  • Putzki N, Fischer J, Gottwald K et al. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur. J. Neurol. 16(6), 713–720 (2009).
  • Haselkorn JK, Balsdon Richer C, Fry Welch D; Multiple Sclerosis Council for Clinical Practice Guidelines. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J. Spinal Cord Med. 28(2), 167–199 (2005).
  • Simeons S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 6, 2950–2966 (2009).
  • Kesselring J. Evidence-based medicine and multiple sclerosis: figures and stories. Neuroepidemiology 35(2), 100 (2010).
  • Bensmail D, Ward AB, Wissel J et al. Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity. Neurorehabil. Neural. Repair 23(6), 546–552 (2009).
  • Nance P, Schryvers O, Schmidt B, Dubo H, Loveridge B, Fewer D. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can. J. Neurol. Sci. 22(1), 22–29 (1995).
  • Ordia JI, Fischer E, Adamski E, Spatz EL. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J. Neurosurg. 85(3), 452–457 (1996).
  • Becker WJ, Harris CJ, Long ML, Ablett DP, Klein GM, DeForge DA. Long-term intrathecal baclofen therapy in patients with intractable spasticity. Can. J. Neurol. Sci. 22(3), 208–217 (1995).
  • Rushton DN, Lloyd AC, Anderson PM. Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity. Pharmacoeconomics 20(12), 827–837 (2002).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.